What is Aclaris Therapeutics's pre-tax income?

Aclaris Therapeutics (ACRS) reported pre-tax income of -$33.02M in Q4 2024.

How has Aclaris Therapeutics's pre-tax income changed year-over-year?

Aclaris Therapeutics's pre-tax income decreased by 48.6% year-over-year, from -$22.21M to -$33.02M.

What is the long-term trend for Aclaris Therapeutics's pre-tax income?

Over 3 years (2021 to 2024), Aclaris Therapeutics's pre-tax income has grown at a 13.3% compound annual growth rate (CAGR), from -$90.87M to -$132.07M.

What does pre-tax income mean?

Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.

Aclaris Therapeutics ACRS Pre-Tax Income

Discontinued — last reported Q4 '24

Pre-Tax Income at other companies

IncyteINCY

$343.6M+46.7%

Corvus PharmaceuticalsCRVS

-$13.09M-183%

Avalo TherapeuticsAVTX

-$19.62M-49.3%

Apogee Therapeutics, Inc.APGE

-$74.03M-34.0%

CytomX TherapeuticsCTMX

-$18.19M-177%

AnaptysBio, Inc.ANAB

-$52.84M-34.5%

Segments

By segment

See full

Single Reportable-$19.82M-31.4%

Other financials

Income statement

See full

Revenue$2.0M+37.2%

Gross profit$1.6M+68.7%

Operating income-$22.2M-22.7%

Net income-$19.8M-31.4%

EPS (diluted)-$0.15-25.0%

Balance sheet

See full

Cash & equivalents$28.7M-5.6%

Total debt$2.0M-20.1%

Total equity$143.6M-0.3%

Total assets$198.7M+0.3%

Cash flow

See full

Operating cash flow-$18.1M-39.0%

CapEx$13.0K-69.8%

Free cash flow-$18.2M-38.6%

Valuation

See full

Market cap$685.75M+337%

Enterprise value$659.07M+410%

P/S82×+73.1×

Profitability

See full

Gross margin76.3%-9.7pp

Operating margin-961.9%+259pp

Net margin-832.6%+132pp

FCF margin-624.9%—

Returns & leverage

See full

Return on equity-48.4%-15.4pp

Debt / equity0×0.0×

Current ratio4×-1.0×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest.

The official record: Aclaris Therapeutics’s 10-K, filed February 27, 2025, on SEC EDGAR. View the filing →

Ask your AI about Aclaris Therapeutics's pre-tax income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aclaris Therapeutics's pre-tax income?: Aclaris Therapeutics (ACRS) reported pre-tax income of -$33.02M in Q4 2024.
How has Aclaris Therapeutics's pre-tax income changed year-over-year?: Aclaris Therapeutics's pre-tax income decreased by 48.6% year-over-year, from -$22.21M to -$33.02M.
What is the long-term trend for Aclaris Therapeutics's pre-tax income?: Over 3 years (2021 to 2024), Aclaris Therapeutics's pre-tax income has grown at a 13.3% compound annual growth rate (CAGR), from -$90.87M to -$132.07M.
What does pre-tax income mean?: Total income from all sources — operating income plus non-operating items like interest income, investment gains, and other income — before the provision for income taxes.